GLP-1R agonists (e.g., exendin-4 and liraglutide) reduce APP expression and processing in the brains of AD model mice through the activation of GLP-1R, decrease A protein production and plaque aggregation, and thus improve their spatial memory capacity (McClean et al., 2015
The least squares mean change compared to placebo is -10.7 with 4 mg retatrutide, -21.6 with 8 mg, and -18.7 with 12 mg
A modest increase in heart rate was also observed, a signal seen with other incretin-based weight-loss agents
These medications significantly decrease appetite and promote early satiety, often leading to substantial reductions in daily food consumption
However, because this is a prescription medication, you should pack it separately from your other carry-on liquids
Retatrutide, a triple GIP, GLP-1, and glucagon receptor agonist in adults with obesity